Pain relief with oral cannabinoids in familial Mediterranean fever

Cannabinoids have analgesic and, possibly, anti‐inflammatory properties but their clinical use has been restricted by legislation. This is the first United Kingdom report of the controlled use of a standardised pharmaceutical preparation of cannabinoids in capsular form. The therapy was assessed in...

Full description

Saved in:
Bibliographic Details
Published in:Anaesthesia 1997-05, Vol.52 (5), p.483-486
Main Authors: Holdcroft, A., Smith, M., Jacklin, A., Hodgson, H., Smith, B., Newton, M., Evans, F.
Format: Article
Language:English
Subjects:
Administration, Oral
Adult
Analgesia - methods
Analgesics
Analgesics, Non-Narcotic - therapeutic use
Biological and medical sciences
Chronic Disease
Complications
Cross-Over Studies
Double-Blind Method
Dronabinol - therapeutic use
Drug Administration Schedule
Familial Mediterranean Fever - drug therapy
familial Mediterranean fever. Pain
Humans
Male
management. Pharmacology
Medical sciences
Neuropharmacology
Pharmacology. Drug treatments
tetrahydrocannabinol
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cannabinoids have analgesic and, possibly, anti‐inflammatory properties but their clinical use has been restricted by legislation. This is the first United Kingdom report of the controlled use of a standardised pharmaceutical preparation of cannabinoids in capsular form. The therapy was assessed in a patient with familial Mediterranean fever, who presented with chronic relapsing pain and inflammation of gastrointestinal origin. After determining a suitable analgesic dosage, a double‐blind placebo‐controlled cross‐over trial was conducted using 50 mg tetrahydrocannabinol daily in five doses in the active weeks and measuring effects on parameters of inflammation and pain. Although no anti‐inflammatory effects of tetrahydrocannabinol were detected during the trial, a highly significant reduction (p 
ISSN:0003-2409
1365-2044
DOI:10.1111/j.1365-2044.1997.139-az0132.x